-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, CSPC Group announced that it has completed the acquisition of 100% equity of Zhuhai Zhifan from an independent third party, which owns 51% equity of Guangzhou Mingkang Biological Engineering Co.
, Ltd.
(hereinafter referred to as Mingkang Bio), and will inject the amount of capital.
154 million yuan
.
According to public information, Mingkang Bio was established in 2000.
The core product, Mingfule, is a third-generation specific thrombolytic drug with intellectual property that was exclusively marketed in 2015.
It is mainly used for the treatment of patients with acute myocardial infarction within 6 hours of onset
.
Analysts believe that CSPC's acquisition of Mingkang Biology may be intended to make up for the possible decline in performance after NBP expires
.
It is understood that the core variety of butylphthalide soft capsules (Note: NBP) and its preparation process under CSPC for the treatment of stroke will expire at the end of 2023
.
In fact, in the announcement, CSPC mentioned that Mingfule has good business potential.
It believes that the acquisition will further strengthen CSPC's product pipeline and provide new growth drivers
.
Of course, regarding CSPC's investment in the acquisition of a Biotech company, some insiders believe that this is actually a microcosm of how domestic traditional big pharmaceutical companies will accelerate the pace of innovation through acquisitions
.
In recent years, as domestic innovation has gradually entered the deep water area, a large number of pharmaceutical companies are using acquisitions to accelerate the pace of innovation
.
For example, on August 9, 2021, Betta Pharmaceuticals announced that it would subscribe for 2.
552 million newly issued B preferred shares of Shuanghong Biotechnology Company in the United States with its own funds of not more than US$5 million
.
At the same time, Hangzhou Beiming Equity Investment Fund Partnership, a related party, subscribed for 2.
552 million B preferred shares newly issued by Shuanghong Technology at the same amount and price
.
According to the data, Shuanghong Technology is an innovative company in the field of life sciences.
It has two innovative technology platforms, "Enzyme Catalytic Drug Discovery Platform" and "Natural Product Biosynthesis Platform".
Based on these technology platforms, Shuanghong Technology has developed Diversified product pipeline
.
Prior to this, China Resources Pharma also issued an announcement stating that Beijing Pharmaceutical Investment Management (BVI) Co.
, Ltd.
, a wholly-owned subsidiary of the company (as the buyer), and Yue Cheng International Capital (HK) Limited, Hualida Development Co.
Limited, Ren Xiaojuan and Bei Ni Ltd (as the seller) entered into a share purchase agreement for a total consideration of approximately HK$799.
7 million to purchase 10% of the shares of Yongtai Biopharmaceuticals
.
It is understood that China Resources Pharma plans to acquire a 10.
0% stake in Yongtai for HK$800 million, mainly to take advantage of its advantages in cellular immunotherapy to complete the strategic layout in the field of cellular immunotherapy
.
According to public information, Yongtai Bio is an innovative biotechnology company engaged in the research and development of cellular immunotherapy products.
Together with its subsidiaries (collectively referred to as "Yongtai Group"), it has been deeply involved in the field of cellular immunotherapy for about 15 years and has established an experienced R&D team.
And a multi-faceted technology platform, and has obtained the relevant intellectual property rights of core technologies and products
.
In general, in the long run, the domestic valuation of the pharmaceutical innovation industry is still relatively high
.
Therefore, under the influence of problems such as the long R&D cycle of innovative drugs and the large demand for funds, more and more traditional large-scale enterprises may need to rely on external forces to achieve their own innovation and development in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
, Ltd.
(hereinafter referred to as Mingkang Bio), and will inject the amount of capital.
154 million yuan
.
According to public information, Mingkang Bio was established in 2000.
The core product, Mingfule, is a third-generation specific thrombolytic drug with intellectual property that was exclusively marketed in 2015.
It is mainly used for the treatment of patients with acute myocardial infarction within 6 hours of onset
.
Analysts believe that CSPC's acquisition of Mingkang Biology may be intended to make up for the possible decline in performance after NBP expires
.
It is understood that the core variety of butylphthalide soft capsules (Note: NBP) and its preparation process under CSPC for the treatment of stroke will expire at the end of 2023
.
In fact, in the announcement, CSPC mentioned that Mingfule has good business potential.
It believes that the acquisition will further strengthen CSPC's product pipeline and provide new growth drivers
.
Of course, regarding CSPC's investment in the acquisition of a Biotech company, some insiders believe that this is actually a microcosm of how domestic traditional big pharmaceutical companies will accelerate the pace of innovation through acquisitions
.
In recent years, as domestic innovation has gradually entered the deep water area, a large number of pharmaceutical companies are using acquisitions to accelerate the pace of innovation
.
For example, on August 9, 2021, Betta Pharmaceuticals announced that it would subscribe for 2.
552 million newly issued B preferred shares of Shuanghong Biotechnology Company in the United States with its own funds of not more than US$5 million
.
At the same time, Hangzhou Beiming Equity Investment Fund Partnership, a related party, subscribed for 2.
552 million B preferred shares newly issued by Shuanghong Technology at the same amount and price
.
According to the data, Shuanghong Technology is an innovative company in the field of life sciences.
It has two innovative technology platforms, "Enzyme Catalytic Drug Discovery Platform" and "Natural Product Biosynthesis Platform".
Based on these technology platforms, Shuanghong Technology has developed Diversified product pipeline
.
Prior to this, China Resources Pharma also issued an announcement stating that Beijing Pharmaceutical Investment Management (BVI) Co.
, Ltd.
, a wholly-owned subsidiary of the company (as the buyer), and Yue Cheng International Capital (HK) Limited, Hualida Development Co.
Limited, Ren Xiaojuan and Bei Ni Ltd (as the seller) entered into a share purchase agreement for a total consideration of approximately HK$799.
7 million to purchase 10% of the shares of Yongtai Biopharmaceuticals
.
It is understood that China Resources Pharma plans to acquire a 10.
0% stake in Yongtai for HK$800 million, mainly to take advantage of its advantages in cellular immunotherapy to complete the strategic layout in the field of cellular immunotherapy
.
According to public information, Yongtai Bio is an innovative biotechnology company engaged in the research and development of cellular immunotherapy products.
Together with its subsidiaries (collectively referred to as "Yongtai Group"), it has been deeply involved in the field of cellular immunotherapy for about 15 years and has established an experienced R&D team.
And a multi-faceted technology platform, and has obtained the relevant intellectual property rights of core technologies and products
.
In general, in the long run, the domestic valuation of the pharmaceutical innovation industry is still relatively high
.
Therefore, under the influence of problems such as the long R&D cycle of innovative drugs and the large demand for funds, more and more traditional large-scale enterprises may need to rely on external forces to achieve their own innovation and development in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
